NewsBite

This ASX biotech stock could be the next M&A target

Joanne Tran
Joanne TranMarkets reporter
EmailLinkedInTwitterFacebook

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Andrew Hamilton is a portfolio manager at Antares Equities. The Melbourne-based firm oversees about $5.7 billion.

Which stock in your funds could be an M&A target and why?

Loading...
Joanne Tran is a markets reporter for The Australian Financial Review in the Sydney newsroom. Connect with Joanne on Twitter. Email Joanne at jo.tran@afr.com
EmailLinkedInTwitterFacebook

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

License article

Read More

Latest In Equity markets

Fetching latest articles

Most Viewed In Markets

    The Australian Financial Review Magazine

    BOSS Financial Review

    SPC CEO Robert Iervasi

    Life & Leisure

    Rich List

    Original URL: https://www.afr.com/markets/equity-markets/this-asx-biotech-stock-could-be-the-next-m-and-a-target-20241205-p5kw06